Multi-Family Office

Updated:

Santo Holding AG

Santo Holding AG was established in 2001 by Andreas and Thomas Strüngmann. The brothers built the firm on proceeds from the 2005 sale of their generic-drug...

Santo Holding AG logo

Santo Holding AG

Santo Holding AG was established in 2001 by Andreas and Thomas Strüngmann. The brothers built the firm on proceeds from the 2005 sale of their generic-drug company Hexal to Novartis. The office directs capital into biotechnology, pharmaceuticals, and healthcare ventures. It supports companies from initial research through later commercial phases. Confirmed relationships include co-investments alongside Dietmar Hopp and MIG AG in German biotech projects, as well as long-standing ties to BioNTech co-founder Ugur Sahin. Geographic focus centers on Germany and Switzerland. The firm maintains a small number of named real-estate holdings in Frankfurt and Munich. It also supports the Ernst Strüngmann Foundation and the Ernst Strüngmann Institute for Neuroscience in cooperation with the Max Planck Society. No public data exist on headcount or total deployment.

General information

Firm type

Multi Family Office

Year founded

2001

Location

Region

Europe

Country

Switzerland

City

Zug

Corporate office

Bundesplatz 2, CH-6300 Zug, Switzerland

Principals

Andreas Strüngmann

Founder

Thomas Strüngmann

Founder

Helmut Wolfgang Jeggle

Business Partner

Sector focus

BiotechnologyPharmaceuticalsHealthcareLife Sciences

Frequently asked questions

Who runs investment decisions at Santo Holding AG?

Andreas and Thomas Strüngmann direct the office as founders. Helmut Wolfgang Jeggle participates as a business partner through Athos Service GmbH.

How does Santo Holding AG source proprietary deal flow?

The firm draws on long-standing relationships with German biotech entrepreneurs and co-investors such as Dietmar Hopp and MIG AG.

Does Santo Holding AG participate in fund commitments or only direct deals?

Public information shows a pattern of direct investments and co-investments in individual biotechnology companies rather than broad fund commitments.

Where does the underlying wealth come from?

The capital originates from the 2005 sale of Hexal, the generic-drug company founded by Andreas and Thomas Strüngmann, to Novartis.

Does Santo Holding AG maintain philanthropic structures?

Yes. The firm supports the Ernst Strüngmann Foundation and the Ernst Strüngmann Institute for Neuroscience in partnership with the Max Planck Society.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on family offices?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

Browse by category

More Zug Multi Family Office profiles